Haralambieva Iana H, Painter Scott D, Kennedy Richard B, Ovsyannikova Inna G, Lambert Nathaniel D, Goergen Krista M, Oberg Ann L, Poland Gregory A
Mayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America.
Mayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America.
PLoS One. 2015 Mar 27;10(3):e0122282. doi: 10.1371/journal.pone.0122282. eCollection 2015.
Although influenza causes significant morbidity and mortality in the elderly, the factors underlying the reduced vaccine immunogenicity and efficacy in this age group are not completely understood. Age and immunosenescence factors, and their impact on humoral immunity after influenza vaccination, are of growing interest for the development of better vaccines for the elderly.
We assessed associations between age and immunosenescence markers (T cell receptor rearrangement excision circles - TREC content, peripheral white blood cell telomerase - TERT expression and CD28 expression on T cells) and influenza A/H1N1 vaccine-induced measures of humoral immunity in 106 older subjects at baseline and three timepoints post-vaccination.
TERT activity (TERT mRNA expression) was significantly positively correlated with the observed increase in the influenza-specific memory B cell ELISPOT response at Day 28 compared to baseline (p-value=0.025). TREC levels were positively correlated with the baseline and early (Day 3) influenza A/H1N1-specific memory B cell ELISPOT response (p-value=0.042 and p-value=0.035, respectively). The expression and/or expression change of CD28 on CD4+ and/or CD8+ T cells at baseline and Day 3 was positively correlated with the influenza A/H1N1-specific memory B cell ELISPOT response at baseline, Day 28 and Day 75 post-vaccination. In a multivariable analysis, the peak antibody response (HAI and/or VNA at Day 28) was negatively associated with age, the percentage of CD8+CD28 low T cells, IgD+CD27- naïve B cells, and percentage overall CD20- B cells and plasmablasts, measured at Day 3 post-vaccination. The early change in influenza-specific memory B cell ELISPOT response was positively correlated with the observed increase in influenza A/H1N1-specific HAI antibodies at Day 28 and Day 75 relative to baseline (p-value=0.007 and p-value=0.005, respectively).
Our data suggest that influenza-specific humoral immunity is significantly influenced by age, and that specific markers of immunosenescence (e.g., the baseline/early expression of CD28 on CD4+ and/or CD8+ T cells and T cell immune abnormalities) are correlated with different humoral immune response outcomes observed after vaccination in older individuals, and thus can be potentially used to predict vaccine immunogenicity.
尽管流感在老年人中会导致显著的发病率和死亡率,但该年龄组疫苗免疫原性和效力降低的潜在因素尚未完全明确。年龄和免疫衰老因素及其对流感疫苗接种后体液免疫的影响,对于开发更适合老年人的疫苗愈发受到关注。
我们评估了106名老年受试者在基线及接种疫苗后三个时间点时,年龄与免疫衰老标志物(T细胞受体重排切除环——TREC含量、外周血白细胞端粒酶——TERT表达以及T细胞上的CD28表达)之间的关联,以及甲型H1N1流感疫苗诱导的体液免疫指标。
与基线相比,在第28天时,TERT活性(TERT mRNA表达)与流感特异性记忆B细胞ELISPOT反应的观察到的增加显著正相关(p值 = 0.025)。TREC水平与基线及早期(第3天)甲型H1N1流感特异性记忆B细胞ELISPOT反应呈正相关(分别为p值 = 0.042和p值 = 0.035)。在基线和第3天时,CD4⁺和/或CD8⁺T细胞上CD28的表达和/或表达变化与接种疫苗后基线、第28天和第75天的甲型H1N1流感特异性记忆B细胞ELISPOT反应呈正相关。在多变量分析中,峰值抗体反应(第28天的血凝抑制试验和/或病毒中和试验)与年龄、接种疫苗后第3天测量的CD8⁺CD28低表达T细胞百分比、IgD⁺CD27⁻幼稚B细胞百分比以及总体CD20⁻B细胞和浆母细胞百分比呈负相关。流感特异性记忆B细胞ELISPOT反应的早期变化与相对于基线在第28天和第75天时观察到的甲型H1N1流感特异性血凝抑制抗体增加呈正相关(分别为p值 = 0.007和p值 = 0.005)。
我们的数据表明,流感特异性体液免疫受年龄显著影响,并且免疫衰老的特定标志物(例如,CD4⁺和/或CD8⁺T细胞上CD28的基线/早期表达以及T细胞免疫异常)与老年个体接种疫苗后观察到的不同体液免疫反应结果相关,因此有可能用于预测疫苗免疫原性。